XML 332 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE RECOGNITION
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
We generated net sales in the following geographic locations(1) (in millions):
Year Ended
December 31, 2024December 31, 2023December 31, 2022
U.S.$2,649.3 $2,916.8 $2,870.0 
Europe(2)
1,604.6 1,622.5 1,474.3 
All other countries(3)
119.5 116.3 107.3 
Total net sales$4,373.4 $4,655.6 $4,451.6 
(1)    The net sales by geography is derived from the location of the entity that sells to a third party.
(2)    Includes Ireland net sales of $39.6 million, $40.8 million, and $29.3 million for the years ended December 31, 2024, December 31, 2023, and December 31, 2022, respectively.
(3)    Includes revenue generated primarily in Australia and Canada during the years ended December 31, 2024 and 2023. During the year ended December 31, 2022, includes revenue generated primarily in Australia, Canada, and Mexico.
Product Category

The following is a summary of our net sales by category (in millions):

Year Ended
December 31, 2024December 31, 2023December 31, 2022
CSCA(1)
Upper Respiratory$500.3 $561.4 $567.3 
Digestive Health497.4 507.5 498.8 
Nutrition449.5 563.2 524.3 
Pain and Sleep-Aids345.5 397.2 412.8 
Healthy Lifestyle306.8 311.4 287.9 
Oral Care275.4 310.4 315.4 
Skin Care220.1 240.5 237.6 
Women's Health81.1 48.6 47.4 
Vitamins, Minerals, and Supplements ("VMS")14.5 18.5 28.3 
Other CSCA(2)
3.1 3.6 6.1 
Total CSCA2,693.7 2,962.3 2,925.9 
CSCI
Skin Care410.0 372.5 334.6 
Upper Respiratory282.1 299.1 268.7 
Healthy Lifestyle225.8 225.7 209.7 
Pain and Sleep-Aids222.2 222.9 200.2 
VMS173.5 185.5 183.9 
Women's Health132.8 119.7 96.1 
Oral Care99.4 101.5 94.8 
Digestive Health36.5 41.0 35.5 
Other CSCI(2)
97.3 125.4 102.2 
Total CSCI1,679.6 1,693.3 1,525.7 
Total net sales$4,373.4 $4,655.6 $4,451.6 
(1)    We updated our global reporting product categories as a result of legacy sales being moved out of Other CSCA and into respective categories. These product categories have been adjusted retroactively to reflect the changes and have no impact on historical financial position, results of operations, or cash flows.
(2)    Consisted primarily of our Rare Diseases Business in CSCI and other miscellaneous or otherwise uncategorized product lines in CSCA and CSCI, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $306.2 million, $337.3 million, and $350.1 million for the years ended December 31, 2024, December 31, 2023, and December 31, 2022, respectively.

The following table provides information about contract assets from contracts with customers (in millions):
Balance Sheet LocationDecember 31, 2024December 31, 2023
Short-term contract assetsPrepaid expenses and other current assets$43.9 $28.5